Literature DB >> 19427791

Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives.

Jean L Santos1, Paulo R Yamasaki, Chung Man Chin, Célio H Takashi, Fernando R Pavan, Clarice Q F Leite.   

Abstract

New phthalimide derivatives were easily prepared through condensation of phthalic anhydride and selected amines with variable yields (70-90%). All compounds (3a-l) were evaluated against Mycobacterium tuberculosis H(37)Rv using Alamar Blue susceptibility. The compounds 3c, 3i, and 3l have the minimum inhibitory concentrations (MICs) of 3.9, 7.8, and 5.0 microg/mL, respectively, and could be considered new lead compounds in the treatment of tuberculosis and multi-drug resistant tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427791     DOI: 10.1016/j.bmc.2009.04.042

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

1.  Synthesis, Molecular Modeling Study, and Quantum-Chemical-Based Investigations of Isoindoline-1,3-diones as Antimycobacterial Agents.

Authors:  Iqrar Ahmad; Rahul H Pawara; Rukaiyya T Girase; Asama Y Pathan; Vilas R Jagatap; Nisheeth Desai; Yusuf Oloruntoyin Ayipo; Sanjay J Surana; Harun Patel
Journal:  ACS Omega       Date:  2022-06-10

2.  A New Isoindoline Based Schiff Base Derivative as Cu(II) Chemosensor: Synthesis, Photophysical, DNA Binding and Molecular Docking Studies.

Authors:  Pattan Sirajuddin Nayab; Madhusudana Pulaganti; Suresh Kumar Chitta
Journal:  J Fluoresc       Date:  2015-09-26       Impact factor: 2.217

3.  Inhibition of the HIF1α-p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II).

Authors:  Madura K P Jayatunga; Sam Thompson; Tawnya C McKee; Mun Chiang Chan; Kelie M Reece; Adam P Hardy; Rok Sekirnik; Peter T Seden; Kristina M Cook; James B McMahon; William D Figg; Christopher J Schofield; Andrew D Hamilton
Journal:  Eur J Med Chem       Date:  2014-06-27       Impact factor: 6.514

4.  Phthalimide analogs as probable 15-lipoxygenase-1 inhibitors: synthesis, biological evaluation and docking studies.

Authors:  Alireza Aliabadi; Ahmad Mohammadi-Farani; Zeinab Hosseinzadeh; Hamid Nadri; Alireza Moradi; Farahnaz Ahmadi
Journal:  Daru       Date:  2015-07-22       Impact factor: 3.117

Review 5.  Anti-Inflammatory Drug Design Using a Molecular Hybridization Approach.

Authors:  Priscila Longhin Bosquesi; Thais Regina Ferreira Melo; Ednir Oliveira Vizioli; Jean Leandro Dos Santos; Man Chin Chung
Journal:  Pharmaceuticals (Basel)       Date:  2011-10-27

6.  Discovery of novel phthalimide analogs: Synthesis, antimicrobial and antitubercular screening with molecular docking studies.

Authors:  Heba S Rateb; Hany E A Ahmed; Sahar Ahmed; Saleh Ihmaid; Tarek H Afifi
Journal:  EXCLI J       Date:  2016-12-06       Impact factor: 4.068

7.  Design and Synthesis of 4-flurophthalimides as potential anticonvulsant agents.

Authors:  Maryam Iman; Sina Fakhari; Mohammad Jahanpanah; Nima Naderi; Asghar Davood
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

8.  Synthesis, anti-mycobacterial and cytotoxic evaluation of substituted isoindoline-1,3-dione-4-aminoquinolines coupled via alkyl/amide linkers.

Authors:  Anu Rani; Albertus Viljoen; Matt D Johansen; Laurent Kremer; Vipan Kumar
Journal:  RSC Adv       Date:  2019-03-13       Impact factor: 4.036

9.  Anti-Mycobacterium tuberculosis activity of fungus Phomopsis stipata.

Authors:  Karina Andrade de Prince; Renata Sordi; Fernando Rogério Pavan; Adolfo Carlos Barreto Santos; Angela R Araujo; Sergio R A Leite; Clarice Q F Leite
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

10.  Novel HDAC/Tubulin Dual Inhibitor: Design, Synthesis and Docking Studies of α-Phthalimido-Chalcone Hybrids as Potential Anticancer Agents with Apoptosis-Inducing Activity.

Authors:  Ahmed A E Mourad; Mai A E Mourad; Peter G Jones
Journal:  Drug Des Devel Ther       Date:  2020-08-03       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.